Novo Nordisk A/S
Novo Nordisk A/S NVO Peers
See (NVO) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVO | $69.50 | +1.31% | 311.2B | 19.41 | $3.58 | +2.33% |
| LLY | $722.39 | +0.42% | 684.6B | 58.92 | $12.26 | +0.78% |
| AZN | $70.87 | +0.70% | 439.4B | 28.58 | $2.48 | +2.18% |
| JNJ | $153.57 | +0.75% | 369.5B | 17.06 | $9.00 | +3.28% |
| ABBV | $185.56 | +1.35% | 327.8B | 79.30 | $2.34 | +3.44% |
| NVS | $112.52 | +0.58% | 222.2B | 17.64 | $6.38 | +3.55% |
| MRK | $76.38 | +0.28% | 191.8B | 11.10 | $6.88 | +4.15% |
| AMGN | $283.54 | +1.85% | 152.5B | 25.82 | $10.98 | +3.28% |
| GILD | $111.11 | +2.46% | 138.2B | 14.36 | $7.74 | +2.80% |
| PFE | $23.45 | +1.16% | 133.3B | 16.99 | $1.38 | +7.28% |
Stock Comparison
NVO vs LLY Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, LLY has a market cap of 684.6B. Regarding current trading prices, NVO is priced at $69.50, while LLY trades at $722.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas LLY's P/E ratio is 58.92. In terms of profitability, NVO's ROE is +0.81%, compared to LLY's ROE of +0.77%. Regarding short-term risk, NVO is more volatile compared to LLY. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.
NVO vs AZN Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, AZN has a market cap of 439.4B. Regarding current trading prices, NVO is priced at $69.50, while AZN trades at $70.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas AZN's P/E ratio is 28.58. In terms of profitability, NVO's ROE is +0.81%, compared to AZN's ROE of +0.19%. Regarding short-term risk, NVO is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.
NVO vs JNJ Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, JNJ has a market cap of 369.5B. Regarding current trading prices, NVO is priced at $69.50, while JNJ trades at $153.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas JNJ's P/E ratio is 17.06. In terms of profitability, NVO's ROE is +0.81%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, NVO is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.
NVO vs ABBV Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, ABBV has a market cap of 327.8B. Regarding current trading prices, NVO is priced at $69.50, while ABBV trades at $185.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas ABBV's P/E ratio is 79.30. In terms of profitability, NVO's ROE is +0.81%, compared to ABBV's ROE of +0.96%. Regarding short-term risk, NVO is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.
NVO vs NVS Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, NVS has a market cap of 222.2B. Regarding current trading prices, NVO is priced at $69.50, while NVS trades at $112.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas NVS's P/E ratio is 17.64. In terms of profitability, NVO's ROE is +0.81%, compared to NVS's ROE of +0.31%. Regarding short-term risk, NVO is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.
NVO vs MRK Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, MRK has a market cap of 191.8B. Regarding current trading prices, NVO is priced at $69.50, while MRK trades at $76.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas MRK's P/E ratio is 11.10. In terms of profitability, NVO's ROE is +0.81%, compared to MRK's ROE of +0.38%. Regarding short-term risk, NVO is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.
NVO vs AMGN Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, AMGN has a market cap of 152.5B. Regarding current trading prices, NVO is priced at $69.50, while AMGN trades at $283.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas AMGN's P/E ratio is 25.82. In terms of profitability, NVO's ROE is +0.81%, compared to AMGN's ROE of +0.93%. Regarding short-term risk, NVO is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.
NVO vs GILD Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, GILD has a market cap of 138.2B. Regarding current trading prices, NVO is priced at $69.50, while GILD trades at $111.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas GILD's P/E ratio is 14.36. In terms of profitability, NVO's ROE is +0.81%, compared to GILD's ROE of +0.32%. Regarding short-term risk, NVO is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.
NVO vs PFE Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, PFE has a market cap of 133.3B. Regarding current trading prices, NVO is priced at $69.50, while PFE trades at $23.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas PFE's P/E ratio is 16.99. In terms of profitability, NVO's ROE is +0.81%, compared to PFE's ROE of +0.09%. Regarding short-term risk, NVO is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.
NVO vs SNY Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, SNY has a market cap of 129.3B. Regarding current trading prices, NVO is priced at $69.50, while SNY trades at $52.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas SNY's P/E ratio is 18.56. In terms of profitability, NVO's ROE is +0.81%, compared to SNY's ROE of +0.08%. Regarding short-term risk, NVO is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.
NVO vs CELG-RI Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, CELG-RI has a market cap of 98.7B. Regarding current trading prices, NVO is priced at $69.50, while CELG-RI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.81%, compared to CELG-RI's ROE of +0.32%. Regarding short-term risk, NVO is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.
NVO vs BMY Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, BMY has a market cap of 97.4B. Regarding current trading prices, NVO is priced at $69.50, while BMY trades at $47.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas BMY's P/E ratio is 17.85. In terms of profitability, NVO's ROE is +0.81%, compared to BMY's ROE of +0.32%. Regarding short-term risk, NVO is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.
NVO vs GSK Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, GSK has a market cap of 81.2B. Regarding current trading prices, NVO is priced at $69.50, while GSK trades at $40.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas GSK's P/E ratio is 19.43. In terms of profitability, NVO's ROE is +0.81%, compared to GSK's ROE of +0.22%. Regarding short-term risk, NVO is less volatile compared to GSK. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.
NVO vs HZNP Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVO is priced at $69.50, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVO's ROE is +0.81%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVO is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.
NVO vs BIIB Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, BIIB has a market cap of 19.5B. Regarding current trading prices, NVO is priced at $69.50, while BIIB trades at $132.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas BIIB's P/E ratio is 13.12. In terms of profitability, NVO's ROE is +0.81%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, NVO is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.
NVO vs GRFS Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, GRFS has a market cap of 6.9B. Regarding current trading prices, NVO is priced at $69.50, while GRFS trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas GRFS's P/E ratio is 32.15. In terms of profitability, NVO's ROE is +0.81%, compared to GRFS's ROE of +0.03%. Regarding short-term risk, NVO is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.
NVO vs OGN Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, OGN has a market cap of 2.5B. Regarding current trading prices, NVO is priced at $69.50, while OGN trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas OGN's P/E ratio is 3.32. In terms of profitability, NVO's ROE is +0.81%, compared to OGN's ROE of +1.82%. Regarding short-term risk, NVO is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.
NVO vs CTOR Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, CTOR has a market cap of 63.8M. Regarding current trading prices, NVO is priced at $69.50, while CTOR trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas CTOR's P/E ratio is -2.35. In terms of profitability, NVO's ROE is +0.81%, compared to CTOR's ROE of -0.15%. Regarding short-term risk, NVO is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.
NVO vs SCLX Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, SCLX has a market cap of 39.3M. Regarding current trading prices, NVO is priced at $69.50, while SCLX trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas SCLX's P/E ratio is -0.37. In terms of profitability, NVO's ROE is +0.81%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, NVO is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.
NVO vs SCLXW Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, SCLXW has a market cap of 30.9M. Regarding current trading prices, NVO is priced at $69.50, while SCLXW trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.81%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, NVO is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.
NVO vs MIRA Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, MIRA has a market cap of 22.7M. Regarding current trading prices, NVO is priced at $69.50, while MIRA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas MIRA's P/E ratio is -2.85. In terms of profitability, NVO's ROE is +0.81%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, NVO is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.
NVO vs SRXH Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, SRXH has a market cap of 6M. Regarding current trading prices, NVO is priced at $69.50, while SRXH trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas SRXH's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.81%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, NVO is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.
NVO vs CRXT Comparison
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 311.2B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVO is priced at $69.50, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 19.41, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVO's ROE is +0.81%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVO is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.